Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13636302 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2HRH3KDM4EPPARGPPARA | |
| SCHEMBL13636303 | 0.81 | HRH3 (0.41) | SMN1; SMN2HRH3KDM4EPPARGPPARA | |
| SCHEMBL10960958 | 0.78 | APP (0.49) | SMN1; SMN2HRH3KDM4EMEN1KMT2A | |
| SCHEMBL1527681 | 0.75 | KDM4E (0.51) | SMN1; SMN2HRH3KDM4EMMP14MEN1 | |
| SCHEMBL22248702 | 0.73 | HRH3 (0.62) | SMN1; SMN2HRH3KDM4EMEN1KMT2A | |
| SCHEMBL25694673 | 0.72 | SMN1; SMN2 (0.46) | SMN1; SMN2HRH3KDM4EPPARGPPARA | |
| SCHEMBL14088926 | 0.72 | SMN1; SMN2 (0.49) | SMN1; SMN2HRH3KDM4EMEN1KMT2A | |
| SCHEMBL10960952 | 0.72 | APP (0.41) | APP | |
| Triton X SCHEMBL28322387 | 0.71 | CYP3A4 (0.61) | SMN1; SMN2HRH3MEN1KMT2AALDH1A1 | |
| SCHEMBL25194021 | 0.71 | KDM4E (0.47) | SMN1; SMN2HRH3KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304385-B2 | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20090142299-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142299-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | SMN1; SMN2 3603/4885HRH3 3743/4885KDM4E 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.